Loading...
Disclaimer: Informational only — not medical advice. AI hypotheses are not clinically validated. Medic Oath is for informational and educational purposes only — not medical advice. AI-generated hypotheses have not been clinically validated. Always consult a qualified healthcare professional. Privacy · Terms
A rare pigmentation anomaly of the skin characterized by otherwise asymptomatic hyperpigmentation of the skin over the dorsal side of fingers and toes which may rapidly spread towards proximal regions, like genitals, abdomen, and thighs. It is mostly seen in newborns or during the first years of life.
Pentoxifylline inhibits phosphodiesterase-4 (PDE4), reducing TNF-α production and improving blood rheology through decreased fibrinogen levels. Enhanced microcirculation combined with kojic acid dipalmitate's tyrosinase inhibition through copper chelation addresses both vascular and pigmentary components of acral melanosis.
Bilobalide and ginkgolides modulate endothelial nitric oxide synthase (eNOS) expression and reduce endothelin-1 (ET-1) mediated vasoconstriction. Platelet-activating factor (PAF) receptor antagonism by ginkgolides prevents microthrombosis. Enhanced VEGF signaling through PI3K/Akt pathway promotes angiogenesis in acral regions.
Psoralen compounds (8-methoxypsoralen, 5-methoxypsoralen) form DNA cross-links with UVA exposure, triggering controlled apoptosis of hyperpigmented keratinocytes. Simultaneous activation of melanocyte stem cells in hair follicles through Wnt/β-catenin (CTNNB1) pathway and MC1R signaling promotes physiological repigmentation.
Sildenafil inhibits phosphodiesterase-5 (PDE5), increasing cGMP levels and promoting vasodilation through protein kinase G (PKG) activation. Tretinoin normalizes keratinocyte turnover via retinoic acid receptor alpha (RARA) and reduces melanin transfer through decreased melanosome uptake by keratinocytes.
Chebulic acid and ellagitannins in Haritaki inhibit advanced glycation end product (AGE) formation and block receptor for AGE (AGER/RAGE) signaling. This reduces NF-κB activation, inflammatory cytokine production (TNF-α, IL-1β), and prevents microvascular endothelial dysfunction leading to pigmentary changes.
Metformin activates AMP-activated protein kinase (PRKAA1/AMPK) leading to phosphorylation and inactivation of acetyl-CoA carboxylase (ACACA). Reduced fatty acid synthesis decreases membrane fluidity changes that affect tyrosinase trafficking. AMPK activation also suppresses mTORC1 signaling, reducing melanogenesis through decreased MITF expression.
Selective ECE1 inhibition prevents conversion of big endothelin-1 to active endothelin-1, reducing vasoconstriction and ischemia-induced melanocyte activation. Decreased ET-1 signaling through EDNRA and EDNRB receptors prevents upregulation of tyrosinase (TYR) and related enzymes (TYRP1, DCT) in response to hypoxic stress.